Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Methyl Gramine SCHEMBL2519973 | 0.80 | MAPT (1.00) | CYP3A4MAPTHTR6HPGDHTR2A | |
| SCHEMBL30314130 | 0.79 | CHRNB2 (0.61) | CYP3A4MAPTCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL3228289 | 0.76 | CHRNB2 (0.67) | CYP3A4MAPTCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL11495830 | 0.76 | HTR2A (0.71) | CYP3A4MAPTHTR6HPGDHTR2A | |
| SCHEMBL3221608 | 0.75 | EGFR (0.59) | CYP3A4MAPTCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL3868019 | 0.75 | MAPT (0.65) | CYP3A4MAPTHTR6HPGDHTR2A | |
| SCHEMBL11348399 | 0.75 | MAPT (0.65) | CYP3A4MAPTCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL14540350 | 0.74 | CYP3A4 (0.64) | CYP3A4MAPTCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL17911952 | 0.73 | CHRNB2 (0.63) | CYP3A4CHRNB2CHRNA7CHRNA4HPGD | |
| SCHEMBL29951907 | 0.73 | MAPT (0.63) | CYP3A4MAPTHTR6HPGDHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010012397-A1 | N-(INDOL-3-YLALKYL)(HETERO)ARYLAMIDE DERIVATIVES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | BAYER SCHERING PHARMA AG (DE) | 2010-02-04 | — | — | US | disclosed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | disclosed |
| US-4217357-A | Inhibition of thromboxane synthetase with 3-(imidazol-1-ylalkyl)indoles | PFIZER INC. (US) | 1980-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029598-A1 | Extended Benzamide Derivatives as Modulators of the EP2 Receptor | PTGER2, PTGER1, PTGDR2 | CYP3A4 492/4885MAPT 4374/4885CHRNB2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.